Association between VEGF Gene Polymorphisms and In-Stent Restenosis after Coronary Intervention Treated with Bare Metal Stent

Table 1

Patient characteristics. Continuous variables are presented as mean (±SD). Dichotomous variables are presented as number of patients (percentage).

Variable	Control group	Restenosis group	value
Age, years	66.5 (±10.2)	65.7 (±9.8)	0.601
Gender, male	74 (74%)	77 (73.3%)	0.914
Antihypertensive therapy	96 (97.0%)	98 (93.3%)	0.229
Lipid-lowering therapy	90 (91.8%)	95 (90.5%)	0.733
Diabetes mellitus	34 (35.1%)	37 (36.6%)	0.816
Obesity, BMI > 25	79 (82.3%)	77 (74.8%)	0.197
BMI	28.0 (±3.8)	28.1 (±4.4)	0.817
Smoking	13 (13.0%)	8 (7.6%)	0.204
Peripheral vascular disease	13 (13%)	18 (17.1%)	0.396
Chronic renal failure	7 (7%)	3 (2.9%)	0.123
Maximal CKMB level	114.8 (±102.3)	95.3 (±140.3)	0.322
Acute coronary disease	56 (56.6%)	62 (59.0%)	0.720
Angina pectoris	40 (40%)	37 (35.2%)	0.482
Cardiogenic shock (Killip IV)	2 (2%)	4 (3.8%)	0.527
Multi-branch stented	8 (8.0%)	14 (13.3%)	0.004
Total number of stents	1.42 (±0.75)	1.65 (±0.97)	0.056
Total stent length in mm	30.7 (20.7)	38.9 (25.5)	0.119
Stent diameter in mm	3.1 (0.4)	3.2 (2.6)	0.614
Ejection fraction	52.5 (11.2)	52.8 (10)	0.864
Average time to repeated angiogram (years)	2.65 (±2.72)	1.12 (±1.43)	<0.001